Literature DB >> 11953313

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.

Yuval Dor1, Valentin Djonov, Rinat Abramovitch, Ahuva Itin, Glenn I Fishman, Peter Carmeliet, Gadi Goelman, Eli Keshet.   

Abstract

To gain insight into neovascularization of adult organs and to uncover inherent obstacles in vascular endothelial growth factor (VEGF)-based therapeutic angiogenesis, a transgenic system for conditional switching of VEGF expression was devised. The system allows for a reversible induction of VEGF specifically in the heart muscle or liver at any selected schedule, thereby circumventing embryonic lethality due to developmental misexpression of VEGF. Using this system, we demonstrate a progressive, unlimited ramification of the existing vasculature. In the absence of spatial cues, however, abnormal vascular trees were produced, a consequence of chaotic connections with the existing network and formation of irregularly shaped sac-like vessels. VEGF also caused a massive and highly disruptive edema. Importantly, premature cessation of the VEGF stimulus led to regression of most acquired vessels, thus challenging the utility of therapeutic approaches relying on short stimulus duration. A critical transition point was defined beyond which remodeled new vessels persisted for months after withdrawing VEGF, conferring a long-term improvement in organ perfusion. This novel genetic system thus highlights remaining problems in the implementation of pro-angiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953313      PMCID: PMC125962          DOI: 10.1093/emboj/21.8.1939

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  33 in total

1.  Angiogenesis and arteriogenesis--not yet for prescription.

Authors:  A Helisch; W Schaper
Journal:  Z Kardiol       Date:  2000-03

Review 2.  Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease.

Authors:  N van Royen; J J Piek; I Buschmann; I Hoefer; M Voskuil; W Schaper
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

3.  Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability.

Authors:  B P Eliceiri; R Paul; P L Schwartzberg; J D Hood; J Leng; D A Cheresh
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

Review 4.  Gene transfer for angiogenesis in coronary artery disease.

Authors:  R J Laham; M Simons; F Sellke
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

5.  Ischemia-driven angiogenesis.

Authors:  Y Dor; E Keshet
Journal:  Trends Cardiovasc Med       Date:  1997-11       Impact factor: 6.677

6.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.

Authors:  P Lindahl; B R Johansson; P Levéen; C Betsholtz
Journal:  Science       Date:  1997-07-11       Impact factor: 47.728

7.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

Authors:  L E Benjamin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

Review 8.  Therapeutic angiogenesis for ischemic cardiovascular disease.

Authors:  S B Freedman; J M Isner
Journal:  J Mol Cell Cardiol       Date:  2001-03       Impact factor: 5.000

9.  Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression.

Authors:  L Miquerol; B L Langille; A Nagy
Journal:  Development       Date:  2000-09       Impact factor: 6.868

10.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.

Authors:  L E Benjamin; I Hemo; E Keshet
Journal:  Development       Date:  1998-05       Impact factor: 6.868

View more
  104 in total

1.  Getting Tie(2)d up in angiogenesis.

Authors:  Markus Ramsauer; Patricia A D'Amore
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Generation of human adult mesenchymal stromal/stem cells expressing defined xenogenic vascular endothelial growth factor levels by optimized transduction and flow cytometry purification.

Authors:  Uta Helmrich; Anna Marsano; Ludovic Melly; Thomas Wolff; Liliane Christ; Michael Heberer; Arnaud Scherberich; Ivan Martin; Andrea Banfi
Journal:  Tissue Eng Part C Methods       Date:  2011-12-19       Impact factor: 3.056

3.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 4.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

Review 5.  Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.

Authors:  Georges von Degenfeld; Andrea Banfi; Matthew L Springer; Helen M Blau
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

6.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

Authors:  Clare R Ozawa; Andrea Banfi; Nicole L Glazer; Gavin Thurston; Matthew L Springer; Peggy E Kraft; Donald M McDonald; Helen M Blau
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

7.  Physiological angiogenesis is a graded, not threshold, response.

Authors:  Stuart Egginton; Iman Badr; James Williams; David Hauton; Guus C Baan; Richard T Jaspers
Journal:  J Physiol       Date:  2010-11-08       Impact factor: 5.182

Review 8.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

9.  c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia.

Authors:  Khadija Rafiq; Mikhail A Kolpakov; Rachid Seqqat; Jianfen Guo; Xinji Guo; Zhao Qi; Daohai Yu; Bhopal Mohapatra; Neha Zutshi; Wei An; Hamid Band; Archana Sanjay; Steven R Houser; Abdelkarim Sabri
Journal:  Circulation       Date:  2014-02-28       Impact factor: 29.690

10.  Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF164.

Authors:  Veronica Sacchi; Rainer Mittermayr; Joachim Hartinger; Mikaël M Martino; Kristen M Lorentz; Susanne Wolbank; Anna Hofmann; Remo A Largo; Jeffrey S Marschall; Elena Groppa; Roberto Gianni-Barrera; Martin Ehrbar; Jeffrey A Hubbell; Heinz Redl; Andrea Banfi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.